Transient increase in HDL-cholesterol during weight gain by hyperalimentation in healthy subjects

Obesity

Volumn 19, Issue 4, 2011, Pages 812-817

  Lindström, Torbjörn ^a   Kechagias, Stergios ^a   Carlsson, Martin ^b   Nystrom, Fredrik H ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SATURATED FATTY ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CALORIC INTAKE; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; HUMAN EXPERIMENT; HYPERALIMENTATION; INSULIN RESISTANCE; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; SEDENTARY LIFESTYLE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EATING; ENERGY INTAKE; FAST FOODS; FEMALE; HUMANS; HYPERPHAGIA; INTERVENTION STUDIES; LIPOPROTEINS, LDL; MALE; PROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES; WEIGHT GAIN; YOUNG ADULT;

EID: 79953186055     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2010.190     Document Type: Article

References (31)

1. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity N Engl J Med 1989;320:915-924. (Pubitemid 19101597)
2. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch Intern Med 2009;169:659-669.
3. Sauma L, Stenkula KG, Kjølhede P et al. PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 2006;22:60-68. (Pubitemid 43175786)
4. Doggrell SA. Clinical trials with thiazolidinediones in subjects with type 2 diabetes\is pioglitazone any different from rosiglitazone? Expert Opin Pharmacother 2008;9:405-420. (Pubitemid 351291785)
5. Hanefeld M. The role of pioglitazone in modifying the atherogenic lipoprotein profile. Diabetes Obes Metab 2009;11:742-756.
6. Sauma L, Franck N, Paulsson JF et al. Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes. Diabetologia 2007;50:195-201 (Pubitemid 46035868)
7. Thörne A, Lönnqvist F, Apelman J, Hellers G, Arner P. A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int J Obes Relat Metab Disord 2002;26:193-199 (Pubitemid 34151196)
8. Kechagias S, Ernersson A, Dahlqvist O et al.; Fast Food Study Group. Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects. Gut 2008;57:649-654. (Pubitemid 351579979)
9. Erlingsson S, Herard S, Dahlqvist Leinhard O et al.; Fast Food Study Group. Men develop more intraabdominal obesity and signs of the metabolic syndrome after hyperalimentation than women. Metab Clin Exp 2009;58:995-1001
10. Tenenbaum A, Fisman EZ, Motro M, Adler Y Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 2008;45:127-153.
11. Gerhard GT, Ahmann A, Meeuws K et al. Effects of a low-fat diet compared with those of a high-monounsaturated fat diet on body weight, plasma lipids and lipoproteins, and glycemic control in type 2 diabetes. Am J Clin Nutr 2004;80:668-673 (Pubitemid 41115532)
12. Sartorio A, Lafortuna CL, Marinone PG et al. Short-term effects of two integrated, non-pharmacological body weight reduction programs on coronary heart disease risk factors in young obese patients. Diabetes Nutr Metab 2003;16:262-265 (Pubitemid 38035303)
13. Sartorio A, Lafortuna CL, Vangeli V et al. Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr 2001;55:865-869. (Pubitemid 32927052)
14. Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005;81:1298-1306. (Pubitemid 41710230)
15. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr 1992;56:320-328.
16. Shim WS, Do MY Kim SK et al. The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clin Endocrinol (Oxf) 2006;65:453-459 (Pubitemid 44414268)
17. Gasteyger C, Tremblay A. Metabolic impact of body fat distribution J Endocrinol Invest 2002;25:876-883 (Pubitemid 35446355)
18. Goodpaster BH, Krishnaswami S, Resnick H et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 2003;26: 372-379 (Pubitemid 36929058)
19. Shai I, Schwarzfuchs D, Henkin Y et al.; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008;359:229-241 (Pubitemid 352008438)
20. Luoma PV Savolainen MJ, Sotaniemi EA et al. Plasma high-density lipoproteins and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction. Acta Med Scand 1983;214:103-109 (Pubitemid 13005913)
21. Luoma PV Sotaniemi EA, Arranto AJ. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest 1983;43:671-675. (Pubitemid 14212047)
22. Luoma PV Sotaniemi EA, Pelkonen RO. Inverse relationship of serum LDL cholesterol and the LDL/HDL cholesterol ratio to liver microsomal enzyme induction in man. Res Commun Chem Pathol Pharmacol 1983;42:173-176. (Pubitemid 14231626)
23. Luoma PV Sotaniemi EA, Pelkonen RO, Myllylä V V. Plasma high-density lipoprotein cholesterol and hepatic cytochrome P-450 concentrations in epileptics undergoing anticonvulsant treatment. Scand J Clin Lab Invest 1980;40:163-167 (Pubitemid 10132140)
24. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152 (Pubitemid 39071617)
25. Larter CZ, Farrell GC. Insulin resistance, adiponectin, cytokines in NASH which is the best target to treat? J Hepatol 2006;44:253-261 (Pubitemid 43071224)
26. Mitro N, Mak PA, Vargas L et al. The nuclear receptor LXR is a glucose sensor Nature 2007;445:219-223 (Pubitemid 46095727)
27. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003;17:985-993 (Pubitemid 36683707)
28. Saucier SE, Kandutsch AA, Gayen AK, Swahn DK, Spencer TA. Oxysterol regulators of 3-hydroxy-3-methylglutaryl-CoA reductase in liver. Effect of dietary cholesterol. J Biol Chem 1989;264:6863-6869 (Pubitemid 19114797)
29. Wellington CL, Walker EK, Suarez A et al. ABCA1 mRNA and protein distribution patterns predict multiple different roles and levels of regulation Lab Invest 2002;82:273-283 (Pubitemid 34242521)
30. Ferretti G, Bacchetti T, Nègre-Salvayre A et al. Structural modifications of HDL and functional consequences. Atherosclerosis 2006;184:1-7 (Pubitemid 41721062)
31. Shige H, Nestel P, Sviridov D, Noakes M, Clifton P. Effect of weight reduction on the distribution of apolipoprotein A-I in high-density lipoprotein subfractions in obese non-insulin-dependent diabetic subjects. Metab Clin Exp 2000;49:1453-1459